CATX's logo.
Ticker Symbol: CATX

Perspective Therapeutics Inc

Exchange: NYSE MKT LLC Country: US Currency: USD Asset Type: Common Stock CIK:0000728387

Company Profile

the introduction of cesium-131 represents the culmination of decades of work and millions of dollars of investment. top medical centers, hospitals and clinics across the united states are now offering this breakthrough treatment for cancer patients. the word brachytherapy derives from the greek prefix brachy, meaning “short” or “close,” because the titanium capsules containing the radioisotope are implanted directly into the cancerous prostate gland. treatment of cancer using low dose radiation or “seed” brachytherapy was pioneered in the 1960’s as an effective alternative to radical prostatectomy. pioneers in brachytherapy research initially theorized about the use of cesium-131 in a titanium capsule, however scientific and economic limitations at the time prevented its development and iodine-125 emerged as an alternative. beginning in 1967, iodine-125 became the first radioisotope manufactured in a titanium capsule, or seed. while its use continues to this day, many patients and doct

Sector: Manufacturing
Industry: Small Arms, Ordnance, and Ordnance Accessories Manufacturing
Standard Industrial Classification Code (SIC code): 3841
Address: 350 Hills St Ste 106
CEO: Lori Woods
Tags: N/A

Pricing

Last Updated: October 20, 2023 03:00 PM EST
Previous Close: $0.29
Change: $0.01 ( 5.14%)
Days Range: $0.28 - $0.30
Beta: 1.00
52wk. High: $0.72
52wk. Low: $0.20
Ytd. Change 19.27%
50 Day Moving Average: $0.30
200 Day Moving Average: $0.50
Shares Outstanding: 280571026

Valuation

Market Cap: 8.3B
PE Ratio: -
EPS (TTM): 0

Dividends

Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A